Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.58 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TNKS | O95271 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.38 |
| ▸ | GALR3 | O60755 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15758398 | 0.99 | GRIA1 (0.57) | GRIA1GRIA3PDE4DMCL1KDM4E | |
| SCHEMBL6695727 | 0.86 | MCL1 (0.47) | GRIA1GRIA3PDE4DMCL1KDM4E | |
| SCHEMBL10707443 | 0.85 | MCL1 (0.63) | GRIA1GRIA3PDE4DMCL1KDM4E | |
| SCHEMBL18007259 | 0.81 | MCL1 (0.49) | GRIA1GRIA3PDE4DMCL1KDM4E | |
| SCHEMBL6693260 | 0.81 | MCL1 (0.42) | GRIA1GRIA3PDE4DMCL1KDM4E | |
| SCHEMBL4463772 | 0.80 | GRIA1 (0.50) | GRIA1GRIA3PDE4DMCL1KDM4E | |
| SCHEMBL5046202 | 0.78 | GRIA1 (0.48) | GRIA1GRIA3PDE4DMCL1KDM4E | |
| SCHEMBL6698453 | 0.78 | GRIA1 (0.47) | GRIA1GRIA3PDE4DMCL1KDM4E | |
| SCHEMBL1882884 | 0.78 | GRIA1 (0.47) | GRIA1GRIA3PDE4DMCL1KDM4E | |
| Water SCHEMBL4777584 | 0.77 | GRIA1 (0.47) | GRIA1GRIA3PDE4DMCL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10111867-B2 | Process and intermediates for the preparation of perampanel | MAPI PHARMA LTD. (IL) | 2018-10-30 | — | — | US | disclosed |
| US-20180008584-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PERAMPANEL | MAPI PHARMA LTD. (IL) | 2018-01-11 | — | — | US | disclosed |
| EP-3259262-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PERAMPANEL | Mapi Pharma Limited (IL) | 2017-12-27 | — | — | EP | disclosed |
| EP-3024821-B1 | PROCESS FOR THE PREPARATION OF PERAMPANEL | TEVA PHARMACEUTICALS INT GMBH (CH) | 2017-09-27 | — | — | EP | disclosed |
| EP-3024821-B1 | PROCESS FOR THE PREPARATION OF PERAMPANEL | TEVA PHARMACEUTICALS INT GMBH (CH) | 2017-09-27 | — | — | EP | disclosed |
| US-9695147-B2 | Process for the preparation of perampanel | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2017-07-04 | — | — | US | disclosed |
| US-9695147-B2 | Process for the preparation of perampanel | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2017-07-04 | — | — | US | disclosed |
| US-9695147-B2 | Process for the preparation of perampanel | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2017-07-04 | — | — | US | disclosed |
| WO-2016147104-A1 | NOVEL PROCESS FOR THE PREPARATION OF PERAMPANEL AND ITS INTERMEDIATES THEREOF | INTAS PHARMACEUTICALS LTD. (IN) | 2016-09-22 | — | — | WO | disclosed |
| WO-2016132343-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PERAMPANEL | MAPI PHARMA LTD. (IL) | 2016-08-25 | — | — | WO | disclosed |
| EP-1772450-A1 | METHOD FOR PRODUCING 1,2-DIHYDROPYRIDINE-2-ONE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-04-11 | — | — | EP | disclosed |
| US-20060100249-A1 | Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| CN-1245386-C | 1, 2-dihydropyridine compound, preparation method and application thereof | EISAI CO LTD (JP) | 2006-03-15 | — | — | CN | disclosed |
| US-20050245581-A1 | 1, 2-Dihydropyridine compounds, manufacturing method thereof and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-6949571-B2 | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof | EISAI CO., LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| EP-1465626-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIHYDROPYRIDINONE COMPOUNDS AND AN IMMUNOREGULATORY OR AN ANTIINFLAMMATORY AGENT AND THEIR USES | Eisai Co., Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
| US-20040023973-A1 | 1,2-Dihydropyridine compounds, process for preparation of the same and use thereof | CATALYST PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
| CN-1436172-A | 1, 2-dihydropyridine compound, preparation method and application thereof | EISAI CO LTD (JP) | 2003-08-13 | — | — | CN | disclosed |
| WO-2003047577-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIHYDROPYRIDINONE COMPOUNDS AND AN IMMUNOREGULATORY OR AN ANTIINFLAMMATORY AGENT AND THEIR USES | EISAI CO LTD (JP) | 2003-06-12 | — | — | WO | disclosed |
| EP-1300396-A1 | 1,2-DIHYDROPYRIDINE COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | Eisai Co., Ltd. (JP) | 2003-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023973-A1 | 1,2-Dihydropyridine compounds, process for preparation of the same and use thereof | GRIK1, GRIK2, GRIK4 | GRIA1 14/4885GRIA3 58/4885PDE4D 2584/4885 |
| US-20050245581-A1 | 1, 2-Dihydropyridine compounds, manufacturing method thereof and use thereof | GRIK1, GRIK2, GRIK5 | GRIA1 24/4885GRIA3 46/4885PDE4D 1607/4885 |
| US-20180008584-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF PERAMPANEL | PDXK, P2RY1, ADH1A | GRIA1 1230/4885GRIA3 1843/4885PDE4D 1383/4885 |
| US-20060100249-A1 | Pharmaceutical compositions comprising dihydropyridinone compounds and an immunoregulatory or an antiinflammatory agent and their uses | QDPR, PMP22, MAG | GRIA1 449/4885GRIA3 663/4885PDE4D 679/4885 |
| US-10111867-B2 | Process and intermediates for the preparation of perampanel | PDXK, P2RY1, ADH1A | GRIA1 1230/4885GRIA3 1843/4885PDE4D 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.